Yale CRIT conference: blogs on the threats from changes to drug regulation in the US and Europe
Last year a US conference brought together a diverse group of healthcare activists concerned about changes to drug regulations.
One outcome is a series of blogs from participants.
- Seven thoughts on the history and present practices of the FDA and uses of prescription drugs – Donald Light and Joel Lexchin
- Transparency by sleight of hand? – Matthew Herder
- Regulating medical products in the interest of the public – Alain Alsalhani
- Regulators must act in the public interest when considering real world evidence: examples from TB and HIV treatments – Marcus Low and Catherine Tomlinson
- Supporting evidence-informed practice by improving clinical research – Rita Banzi
- Randomised clinical trials will be needed for the foreseeable future – Susan Ellenberg
- What does a pro-patient, pro-public health regulatory agency look like? – Michael Carome
- Federal “right to try” legislation – perpetuating a misguided skepticism towards the FDA – Jeanie Kim
- Patient advocacy must be rooted in evidence and science literacy to make a real difference – Fran Visco
- Are payers willing to engage in evidence-based coverage decisions? – Dan Ollendorf
- What is the state of the evidence base for medical products we use currently? – Tom Jefferson
- Why high quality evidence matters: lessons from HIV activism and drug development – Simon Collins
- Deregulatory pressures on the FDA – Alison Bateman-House and Arthur Caplan